Picton Mahoney Asset Management Cuts Stock Position in Masimo Corporation $MASI

Picton Mahoney Asset Management lessened its holdings in Masimo Corporation (NASDAQ:MASI) by 73.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,970 shares of the medical equipment provider’s stock after selling 32,587 shares during the quarter. Picton Mahoney Asset Management’s holdings in Masimo were worth $1,766,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Jupiter Asset Management Ltd. purchased a new position in shares of Masimo in the 3rd quarter worth about $12,491,000. Westfield Capital Management Co. LP raised its position in Masimo by 75.9% in the second quarter. Westfield Capital Management Co. LP now owns 1,181,203 shares of the medical equipment provider’s stock worth $198,702,000 after acquiring an additional 509,724 shares during the period. 4D Advisors LLC boosted its stake in Masimo by 50.0% in the second quarter. 4D Advisors LLC now owns 45,000 shares of the medical equipment provider’s stock valued at $7,570,000 after acquiring an additional 15,000 shares during the last quarter. ING Groep NV bought a new position in shares of Masimo during the 3rd quarter valued at approximately $3,069,000. Finally, Citigroup Inc. increased its stake in shares of Masimo by 133.5% during the 3rd quarter. Citigroup Inc. now owns 116,672 shares of the medical equipment provider’s stock worth $17,215,000 after purchasing an additional 66,710 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MASI has been the topic of several research analyst reports. Wolfe Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Bank of America started coverage on Masimo in a research note on Monday, November 17th. They issued a “neutral” rating and a $162.00 target price on the stock. Piper Sandler downgraded Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price target for the company. in a research note on Tuesday, February 17th. BTIG Research lowered Masimo from a “buy” rating to a “neutral” rating in a report on Wednesday, February 18th. Finally, Stifel Nicolaus set a $180.00 price objective on Masimo in a research note on Tuesday, February 17th. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $181.17.

Masimo Stock Up 0.1%

Shares of NASDAQ:MASI opened at $175.46 on Friday. The firm has a fifty day moving average price of $146.38 and a two-hundred day moving average price of $144.69. The company has a market cap of $9.42 billion, a price-to-earnings ratio of -16.65, a PEG ratio of 1.78 and a beta of 1.21. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.49 and a quick ratio of 1.92. Masimo Corporation has a one year low of $125.94 and a one year high of $183.49.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.